« Return to News | Drug Sponsors

ARYx Therapeutics to close

Friday, March 11, 2011 01:41 PM

ARYx Therapeutics said it will wind down its operations due to lack of funding after the FDA delayed providing guidance on the trial design of its experimental drug for gastrointestinal disorders, according to Reuters.

In its latest communication with ARYx, the FDA suggested a response on the company's request for a special protocol assessment will not come until July 2011 at the earliest.

FDA was initially supposed to respond to ARYx's request on the drug, naronapride, by Nov. 5, 2010, but had informed the company that the response would be delayed until the end of March.

ARYx said it would start winding down operations effective immediately, to be executed in cooperation with ARYx's largest secured creditors, including Lighthouse Capital Partners V and MPM Capital.

The company said it is likely holders of Aryx common stock and other securities will receive no recovery.

ARYx has been pursuing interim financing and had secured a non-binding term sheet from an investor consortium. However, following the delay in the FDA's response, the consortium has withdrawn all potential financing arrangements.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.